CYTOKINETICS INC

During the quarter ended December 31, 2025, the following of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K:

•

Robert I. Blum, President & Chief Executive Officer – Mr. Blum adopteda trading arrangement on December 24, 2025 intended to satisfy the affirmative defense provided for under Rule 10b5-1(c). Mr. Blum’s trading arrangement provides for the sale of up to 120,000 shares of our common stock andwill terminate on theearlier of (x)November 30, 2026 and (y) the sale of all securities that are subject to the arrangement.

•

Sung Lee, Executive Vice President & Chief Financial Officer – Mr. Leeadopted a trading arrangement on December 23, 2025 intended to satisfy the affirmative defense provided for under Rule 10b5-1(c). Mr. Lee’s trading arrangement provides for the sale of up to 70,107 shares of our common stock andwill terminate on theearlier of (x)December 31, 2026 and (y) the sale of all securities that are subject to the arrangement.

•

Fady Malik, Executive Vice President, Research & Development - Dr. Malik adopteda trading arrangement on December 23, 2025 intended to satisfy the affirmative defense provided for under Rule 10b5-1(c). Dr. Malik’s trading arrangement provides for the sale of up to 62,886 shares of our common stock andwill terminate on theearlier of (x)December 18, 2026 and (y) the sale of all securities that are subject to the arrangement.